A phase 3 pivotal study (118161/118169) and open-label extension (118163) to assess the efficacy and safety of nemolizumab (CD14152) in moderate-to-severe atopic dermatitis subjects and associated pr

Administered By

Awarded By

Contributors

Start/End

  • January 15, 2020 - January 20, 2022